Clinical Trial Services

PhenoPath provides anatomic pathology services for Phase I–III clinical trials. Our team adapts its service delivery to reflect your project design, management and implementation requirements.

PhenoPath is experienced in working with third-party vendors to ensure timely and trackable specimen management, either directly from sponsor sites or another CRO.

PhenoPath understands the need for timely results on entrance criteria testing, and provides rapid turnaround time for biomarker-testing assays. Board-certified pathologists and/or scientists evaluate all assays. Report formats are customizable to reflect either individual case or cumulative case formats.

  • Pathology Services

    DIAGNOSIS & INTERPRETATION

    • Solid tumor diagnosis and subtyping, including breast, colon, lung, sarcoma, etc.
    • Hematopathology diagnosis and subtyping including, lymphoid, myeloid, plasma cell disorders, etc.
    • Tissue biomarker quantification, including flow cytometry, immunohistochemistry (IHC), immunofluorescence (IF), cytogenetics, fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), DNA/RNA in situ hybridization (ISH), and polymerase chain reaction (PCR)
    • Tissue macrodissection for downstream assay(s)
    • Tissue microarray construction
    • Over 450 tests available

     

    EXPERT CONSULTATION

    • Consultation on therapeutic target selection and quantification in the pre-clinical setting
    • Consultation on all pathology-related aspects of clinical trial design, including optimized therapeutic target quantification
    • Second opinion consultation on complex cases, including clinical correlation

     

    CONTINUOUS EDUCATION

    • PhenoPath pathologists follow the latest developments in cancer diagnosis and treatment
    • PhenoPath pathologists publish extensively in scientific peer-reviewed journals
    • PhenoPath Pathology Reference Guide available
    • PhenoPath pathologists are available to present on-site at investigator meetings 

  • Entrance & Enrollment

    RAPID ENTRANCE CRITERIA SCREENING

    • Rapid pathology testing and evaluation by board-certified pathologists and scientists
    • Close coordination with each sponsor's clinical trial organizers

     

    REPORTING CAPABILITIES

    • Custom report formats
    • Scalable and configurable results reporting database
    • Virtual pathology reporting capabilities
    • Secure and encrypted data transfer and archiving

     

    SPECIMEN MANAGEMENT

    • End-to-end specimen acquisition and tracking
    • Rapid-turnaround time for enrollment criteria 

  • Expertise

    SOLID TUMOR PATHOLOGY HEMATOPATHOLOGY
    Diagnosis and subtyping (breast, colon, lung, sarcoma, etc.) Indolent B cell non-Hodgkin lymphoma
    Undifferentiated malignant neoplasms Prognostic and predictive markers
    Carcinomas of unknown primary site Aggressive B cell non-Hodgkin lymphoma
    Spindle cell tumors/sarcoma subtyping T cell non-Hodgkin lymphoma
    Mesothelioma vs. adenocarcinoma Lymphoblastic leukemia / lymphoma
    Small, blue, round cell tumors Hodgkin lymphoma
    Germ cell neoplasms Plasma cell neoplasms
    Skin and mucosal immunofluorescence studies Acute myeloid leukemias
    Chronic myeloid neoplasms (MDS & MPN) Rare hematolymphoid neoplasms
    Hydatidiform mole evaluation Benign hematolymphoid proliferations
    Amyloid subtyping  

Clinical Trials (Flyer)